Showing results (121-130 of 2,507) with videos related to

Sort By:
Pageof 251
Clinical Lymphoma, Myeloma & Leukemia|March 16, 2013
Targeting the Toll-like receptor/interleukin 1 receptor pathway in human diseases: rational design of MyD88 inhibitorsMaria Loiarro, Vito Ruggiero, Claudio Sette
Clinical Lymphoma, Myeloma & Leukemia|March 16, 2013
Survival in monoclonal gammopathy of undetermined significance and Waldenström macroglobulinemiaSigurdur Y Kristinsson, Magnus Björkholm, Ola Landgren
Clinical Lymphoma, Myeloma & Leukemia|March 16, 2013
Familial predisposition to monoclonal gammopathies: deviations in B-cell biologyHelga M Ögmundsdóttir, Sóley Valgeirsdóttir, Heather R Schiffhauer, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 17, 2013
Dissecting karyotypic patterns in non-hyperdiploid multiple myeloma: an overview on the karyotypic evolutionVictor H Jimenez-Zepeda, Esteban Braggio, Rafael Fonseca
Clinical Lymphoma, Myeloma & Leukemia|December 25, 2012
High frequencies of response after limited primary therapy for multiple myelomaRaymond Alexanian, Kay Delasalle, Michael Wang
Clinical Lymphoma, Myeloma & Leukemia|December 25, 2012
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabineElias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 26, 2012
Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II studyAsifa Malik, Mahran Shoukier, Guillermo Garcia-Manero, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 12, 2013
microRNA aberrations in Waldenström macroglobulinemiaAntonio Sacco, Yong Zhang, Patricia Maiso, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2012
Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL studyFrancine Foss, Steven M Horwitz, Bertrand Coiffier, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 9, 2013
Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemiaAlfonso Quintás-Cardama, Hagop Kantarjian, Sherry Pierce, et al.
Pageof 251